Stocks / Healthcare

ProKidney Corp.

PROK Stock Report
Current Price
XXXX
Analyst Target Price
$5.83
Market Cap
XXXX
Updated
September 9, 2025
Analysts
7

ProKidney Corp. Stock Overview

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous … More details ➜
1 Year Price Range
Low $0.46 Current High $5.95
PinkLion Scores

Fundamentals Summary

P/E Ratio
-
P/S Ratio
3,430.06x
Net Income
Revenue
Market Cap

Net Income & Revenue

Last Reported Earnings
June 30, 2025
Earnings per share (EPS) $-0.56
Gross Margin 100.00%
Net Profit Margin -
Debt/Equity Ratio 14.18%

Dividends

Current Dividend Yield
-
Payout Ratio
-
Forward Dividend Yield
-

Price History

Track historical stock performance, price trends, and volatility for PROK to see how the stock has performed over time.
YTD
1 Year
5 Years
All

Valuation Summary

We estimate a fair price for PROK by projecting its future cash flows and discounting them back to today with a XXXXX model.

About the Company

IPO Date
July 12, 2022
Employees
204
Sector
Healthcare
Industry
Biotechnology
Country
USA
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.